Drug intelligence / Profile preview

FPE023

Development stage: Preclinical
Lead developer: Guangdong Fapon Biopharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

FPE023 is a bispecific antibody drug candidate developed by Guangdong Fapon Biopharma. It targets CD3, acting as a T cell surface glycoprotein CD3 inhibitor. The primary therapeutic area for FPE023 is oncology, specifically for the treatment of neoplasms such as colorectal cancer and potentially other digestive system disorders. As of the latest available information, it remains in preclinical development[2].

Targets

CD3E (T-cell surface glycoprotein CD3 epsilon chain)

Beyond the preview

Go deeper on FPE023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FPE023.

Explore the full profile